

Figure S1 Summary of quality assessment included in the study.




Figure S2 Network analysis of general health. (A) Network plots of the comparisons between different interventions. (B) Forest plot of network meta-analysis. (C) Ranking probability plot. (D) Cumulative probability ranking plot.




Figure S3 Network analysis of working performance. (A) Network plots of the comparisons between different interventions. (B) Forest plot of network meta-analysis. (C) Ranking probability plot. (D) Cumulative probability ranking plot.




Figure S4 Network analysis of sexual matters. (A) Network plots of the comparisons between different interventions. (B) Forest plot of network meta-analysis. (C) Ranking probability plot. (D) Cumulative probability ranking plot.




Figure S5 Comparison-adjusted funnel plot of the studies included in this meta-analysis.

Table S1 The characteristics of included studies

Authors	Year	Region	Number of patients	Therapy (daily dosage, sample size)	Start of therapy	Follow-up time (week)
Wang	2009	China	154	Tamsulosin (0.4 mg, n=79), control (n=75)	POD1	1
Lee	2013	China	140	Solifenacin (10 mg, n=70), control (n=70)	POD1	2
Dellis	2014	Greece, United Kingdom	100	Tamsulosin (0.4 mg, n=50), control (n=50)	POD1	4
Singh	2014	India	60	Tamsulosin (0.4 mg, n=30), control (n=30)	POD3	4
Aggarwal	2015	India	101	Tamsulosin (0.4 mg, n=51), control (n=50)	POD7	3
Park	2015	Korea	63	Tamsulosin (0.2 mg, n=20), solifenacin (5 mg, n=20), control (n=23)	POD1	2
El-Nahas	2016	Egypt	131	Tamsulosin (0.4 mg, n=44), solifenacin (5 mg, n=43), control (n=44)	POD1	1 to 2
Abdelhamid	2017	Egypt	140	Solifenacin (10 mg, n=70), control (n=70)	POD1	2
Dellis	2017	Greece	180	Tamsulosin (0.4 mg, n=60), solifenacin (5 mg, n=60), control (n=60)	POD1	4
Ragab	2017	Egypt	243	Solifenacin (5 mg, n=121), control (n=122)	POD1	15 days
Bhattar	2018	India	85	Solifenacin (10 mg, n=43), control (n=42)	POD7	3
Tae	2018	Korea	96	Mirabegron (50 mg, n=48), control (n=48)	POD1	2
Yavuz	2021	Turkey	161	Tamsulosin (0.4 mg, n=55), mirabegron (50 mg, n=50), control (n=56)	POD1	4
Falahatkar	2021	Iran	128	Solifenacin (5 mg, n=64), control (n=64)	POD1	2
Abdelaziz	2022	Saudi Arabia	97	Mirabegron (50 mg, n=34), solifenacin (5 mg, n=32), control (n=31)	POD4	2
Chandna	2022	India	123	Mirabegron (50 mg, n=41), solifenacin (5 mg, n=40), tamsulosin (0.4 mg, n=42)	POD1	4

POD, postoperative day.